Magnetic biosensors for identification of SARS-CoV-2, Influenza, HIV, and Ebola viruses: a review

Nanomaterials-based electrochemical biosensors for diagnosis of COVID-19

Since the outbreak of corona virus disease 2019 (COVID-19), this pandemic has caused severe death and infection worldwide. Owing to its strong infectivity, long incubation period, and nonspecific symptoms, the early diagnosis is essential to reduce risk of the severe illness. The electrochemical biosensor, as a fast and sensitive technique for quantitative analysis of body fluids, has been widely studied to diagnose different biomarkers caused at different infective stages of COVID-19 virus (SARS-CoV-2). Recently, many reports have proved that nanomaterials with special architectures and size effects can effectively promote the biosensing performance on the COVID-19 diagnosis, there are few comprehensive summary reports yet. Therefore, in this review, we will pay efforts on recent progress of advanced nanomaterials-facilitated electrochemical biosensors for the COVID-19 detections. The process of SARS-CoV-2 infection in humans will be briefly described, as well as summarizing the types of sensors that should be designed for different infection processes. Emphasis will be supplied to various functional nanomaterials which dominate the biosensing performance for comparison, expecting to provide a rational guidance on the material selection of biosensor construction for people. Finally, we will conclude the perspective on the design of superior nanomaterials-based biosensors facing the unknown virus in future.

Machine Learning for COVID-19 Determination Using Surface-Enhanced Raman Spectroscopy

The rapid, low cost, and efficient detection of SARS-CoV-2 virus infection, especially in clinical samples, remains a major challenge. A promising solution to this problem is the combination of a spectroscopic technique: surface-enhanced Raman spectroscopy (SERS) with advanced chemometrics based on machine learning (ML) algorithms. In the present study, we conducted SERS investigations of saliva and nasopharyngeal swabs taken from a cohort of patients (saliva: 175; nasopharyngeal swabs: 114). Obtained SERS spectra were analyzed using a range of classifiers in which random forest (RF) achieved the best results, e.g., for saliva, the precision and recall equals 94.0% and 88.9%, respectively. The results demonstrate that even with a relatively small number of clinical samples, the combination of SERS and shallow machine learning can be used to identify SARS-CoV-2 virus in clinical practice.